Source:http://linkedlifedata.com/resource/pubmed/id/12356356
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2002-10-1
|
pubmed:abstractText |
Temozolomide is a novel second-generation oral alkylating agent with demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA). A multicenter phase II trial was conducted to determine the efficacy and safety of temozolomide before radiotherapy in patients with newly diagnosed GBM and AA. Fifty-seven patients (51 adult, 6 pediatric) with newly diagnosed supratentorial GBM or AA were treated with temozolomide (200 mg/m ( 2 ) per day for 5 consecutive days every 28 days) for a maximum of 4 cycles. All patients were then treated with external beam radiotherapy. Twenty-two patients (39%) achieved objective response, including 6 (11%) with complete response (CR) and 16 (28%) with partial response (PR). Additionally, 18 (32%) patients had stable disease (SD). Of 21 patients (18 adult, 3 pediatric) with AA, 2 (10%) achieved CR, 5 (24%) achieved PR, and 8 (38%) had SD. Among adult patients with AA, the median progression-free and overall survival rates were 7.6 and 23.5 months, respectively. Among 36 patients (33 adult, 3 pediatric) with GBM, 4 (11%) had CR, 11 (31%) had PR, and 10 (28%) had SD. The median progression-free and overall survival rates among adult patients with GBM were 3.9 and 13.2 months, respectively. Temozolomide was safe and well tolerated in adult and pediatric patients. Grades 3 and 4 adverse events were reported in 16 (28%) and 7 (12%) patients, respectively. Temozolomide was safe and effective in treating newly diagnosed GBM and AA before radiotherapy. This pre-irradiation treatment approach appears promising, but will require additional evaluation in comparative studies.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1522-8517
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
4
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
261-7
|
pubmed:dateRevised |
2008-11-20
|
pubmed:meshHeading |
pubmed-meshheading:12356356-Adolescent,
pubmed-meshheading:12356356-Adult,
pubmed-meshheading:12356356-Aged,
pubmed-meshheading:12356356-Antineoplastic Agents, Alkylating,
pubmed-meshheading:12356356-Child,
pubmed-meshheading:12356356-Child, Preschool,
pubmed-meshheading:12356356-Dacarbazine,
pubmed-meshheading:12356356-Female,
pubmed-meshheading:12356356-Glioma,
pubmed-meshheading:12356356-Humans,
pubmed-meshheading:12356356-Male,
pubmed-meshheading:12356356-Middle Aged,
pubmed-meshheading:12356356-Multicenter Studies as Topic,
pubmed-meshheading:12356356-Supratentorial Neoplasms,
pubmed-meshheading:12356356-Survival Rate,
pubmed-meshheading:12356356-Treatment Outcome
|
pubmed:year |
2002
|
pubmed:articleTitle |
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.
|
pubmed:affiliation |
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|